Abbott Laboratories (ABT) stock
Close on Nov 11, 2026Market cap $189.11BP/E 40.5Yield 2.20%
Abbott Laboratories grew revenue 10.0% to $48.23B over the twelve months to Sep 30, 2026. Operating income fell 13.8% to $6.65B, moving the operating margin from 17.6% to 13.8%. Free cash flow was $6.76B, down 2.3% from a year earlier. At the latest close the market valued the company at $189.11B, 40.5 times its earnings.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $189.11B
- P/E ratio
- 40.5
- Price to sales
- 3.92
- Price to book
- 3.71
- Dividend yield
- 2.20%
- Free cash flow yield
- 3.57%
Fundamentals
- Revenue
- $48.23B
- Net income
- $4.70B
- EPS, diluted
- $2.70
- Free cash flow
- $6.76B
- Book value per share
- $29.36
- Diluted shares
- 1.74B
Trading
- Next earnings
- Jan 21, 2027 (estimated, before the open)
- Previous close
- $110.46
- Open
- $109.88
- Day's range
- $108.95 – $110.33
- Volume
- 8,970,898
- Average volume (20 days)
- 9,698,883
- Index membership
- S&P 500, Russell 1000, Russell 3000
- Beta (5 years)
- 0.46
- 52-week range
- $81.97 – $132.03
- RSI (14 days)
- 56.3
- Volatility (1 year)
- 28.3%
- Relative volume
- 0.94×
- WACC
- 6.8%
Index membership is inferred from the holdings of funds that track each index (VOO, IVV, SPYM, IWB, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2009, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | ABT | S&P 500 | Difference | ABT per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +10.4% | -2.4% | +12.8 pts | ||
| 3 months | +0.2% | -1.2% | +1.4 pts | ||
| Year to date | -10.6% | +12.3% | −22.9 pts | ||
| 1 year | -11.8% | +12.4% | −24.3 pts | ||
| 3 years | +23.9% | +78.8% | −54.9 pts | +7.4% | +21.4% |
| 5 years | -5.1% | +75.2% | −80.3 pts | -1.0% | +11.9% |
| 10 years | +228.6% | +311.1% | −82.5 pts | +12.6% | +15.2% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Abbott Laboratories filed with the SEC as exhibits to Form 8-K or 6-K
- News
- Results
- Update
- Results
- News
- Abbott Reports First-Quarter 2026 Results; Updates Guidance to Reflect Acquisition of Exact SciencesResults
About Abbott Laboratories
Pharmaceutical Preparations
Abbott Laboratories discovers, develops, manufactures, and sells a diverse line of healthcare products across four primary segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. Its offerings comprise branded generic pharmaceuticals, core laboratory and rapid diagnostic systems, pediatric and adult nutritional items, and medical devices for cardiovascular care, diabetes management, and neuromodulation. The company distributes its solutions to consumers, hospitals, pharmacies, clinical laboratories, healthcare facilities, wholesalers, and government agencies.
Company profile, executives and historyAbbott Laboratories stock: common questions
What is Abbott Laboratories's stock price?
ABT closed at $109.29 on Nov 11, 2026, down 1.06% on the day. Over the past 52 weeks it traded between $81.97 and $132.03.
What is Abbott Laboratories's market cap?
Abbott Laboratories was worth $189.11B at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is ABT's P/E ratio?
ABT trades at 40.5 times earnings, based on diluted earnings per share of $2.70 over the twelve months to Sep 30, 2026.
How much revenue does Abbott Laboratories make?
Abbott Laboratories reported revenue of $48.23B for the twelve months to Sep 30, 2026, up 10.0% from a year earlier.
Does Abbott Laboratories pay a dividend?
Yes. Abbott Laboratories paid $2.40 per share over the last twelve months, a yield of 2.20% at the latest price, and has raised its annual dividend 3 years in a row.
When does Abbott Laboratories report earnings next?
Abbott Laboratories is expected to report Q4 FY2026 results on Jan 21, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has ABT stock performed over the past year?
Including dividends, ABT returned -11.8% over the past year, against +12.4% for the S&P 500.
How many ABT shares are sold short?
19M shares were sold short at the latest FINRA report, 1.11% of the float, or 1.9 days of average trading volume.
Who are Abbott Laboratories's competitors?
Companies most similar to Abbott Laboratories by business, industry and size include ABBV, LLY, JNJ, PFE, VTRS.
See a number that looks wrong?